Galaxy Surfactants Ltd. (IN:GALAXYSURF)
:GALAXYSURF
Want to see IN:GALAXYSURF full AI Analyst Report?
GALAXYSURF Stock Chart & Stats
₹1960.70
₹8.85(0.36%)
At close: 4:00 PM EST
₹1960.70
₹8.85(0.36%)
Day’s Range― - ―
52-Week Range₹1,512.30 - ₹2,750.00
Previous CloseN/A
Volume14.90K
Average Volume (3M)465.00
Market Cap
₹68.57B
Enterprise Value₹62.47B
Total Cash (Recent Filing)₹6.55B
Total Debt (Recent Filing)₹2.68B
Price to Earnings (P/E)26.6
Beta0.95
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.07%
Share Statistics
EPS (TTM)80.79
Shares Outstanding35,454,754
10 Day Avg. Volume455
30 Day Avg. Volume465
Financial Highlights & Ratios
PEG Ratio-1.63
Price to Book (P/B)1.96
Price to Sales (P/S)1.02
P/FCF Ratio29.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)88.93
Revenue Forecast (FY)₹56.79B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and steadily expanding equity provide durable financial flexibility, enabling the company to fund working capital, selective capex or product development and withstand commodity cycles. This conservatism supports resilience through downturns and optionality for strategic investments.
Stable B2B Specialty Chemicals BusinessSupplying essential surfactants to formulators and FMCG makers creates stable, repeatable demand. The B2B specialty focus and broad end-market exposure (home and personal care) foster sticky customer relationships, technical differentiation and the opportunity to grow higher-margin specialty solutions over time.
Improved Cash GenerationA strong FCF rebound restores internal funding capacity for dividends, deleveraging or targeted reinvestment. Consistent positive FCF in 2026 signals operational recovery and increases strategic optionality, though ongoing conversion needs monitoring to ensure durability of cash flows.
Bears Say
Margin ErosionSharp compression in gross and net margins weakens the company's ability to self-fund growth and cushioning against input cost shocks. Sustained margin pressure reduces reinvestment capacity, limits returns to shareholders and indicates potential erosion of pricing power or higher-cost raw material structure.
Earnings Quality / Cash Conversion WeaknessWhen reported earnings are not translating into cash, the business is more exposed to working-capital swings or accounting timing effects. Persistent weak cash conversion constrains dividends, capex and debt reduction, and raises the risk that earnings prove difficult to sustain through cyclical downturns.
Inconsistent Revenue GrowthIrregular top-line performance complicates long-term planning and weakens operating leverage. Periodic declines followed by rebounds suggest exposure to volatile end-market demand or competitive dynamics, which can limit steady margin expansion and make multi-year forecasting and capital allocation harder.
Galaxy Surfactants Ltd. News
GALAXYSURF FAQ
What was Galaxy Surfactants Ltd.’s price range in the past 12 months?
Galaxy Surfactants Ltd. lowest stock price was ₹1512.30 and its highest was ₹2750.00 in the past 12 months.
What is Galaxy Surfactants Ltd.’s market cap?
Galaxy Surfactants Ltd.’s market cap is ₹68.57B.
When is Galaxy Surfactants Ltd.’s upcoming earnings report date?
Galaxy Surfactants Ltd.’s upcoming earnings report date is Aug 11, 2026 which is in 47 days.
How were Galaxy Surfactants Ltd.’s earnings last quarter?
Galaxy Surfactants Ltd. released its earnings results on May 14, 2026. The company reported ₹17.6 earnings per share for the quarter, missing the consensus estimate of ₹20.25 by -₹2.65.
Is Galaxy Surfactants Ltd. overvalued?
According to Wall Street analysts Galaxy Surfactants Ltd.’s price is currently Overvalued.
Does Galaxy Surfactants Ltd. pay dividends?
Galaxy Surfactants Ltd. pays a Semiannually dividend of ₹4 which represents an annual dividend yield of 1.07%. See more information on Galaxy Surfactants Ltd. dividends here
What is Galaxy Surfactants Ltd.’s EPS estimate?
Galaxy Surfactants Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galaxy Surfactants Ltd. have?
Galaxy Surfactants Ltd. has 35,454,754 shares outstanding.
What happened to Galaxy Surfactants Ltd.’s price movement after its last earnings report?
Galaxy Surfactants Ltd. reported an EPS of ₹17.6 in its last earnings report, missing expectations of ₹20.25. Following the earnings report the stock price went up 0.6%.
Which hedge fund is a major shareholder of Galaxy Surfactants Ltd.?
Currently, no hedge funds are holding shares in IN:GALAXYSURF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galaxy Surfactants Ltd.
Established in 1980 and based in Navi Mumbai, India, Galaxy Surfactants Limited operates as a manufacturer and international distributor of specialized chemical ingredients. The company primarily caters to the personal and home care industries, both within India and globally. Its extensive product range encompasses a wide variety of compounds, including fatty alcohol surfactants, ethoxylates, alkyl benzene sulphonic acids, foam and viscosity boosters, mild surfactants, and pearlizers. Additionally, they supply specialized blends, syndet and TBB bases, sun protection agents, preservatives, and a host of specialty additives such as emollients, conditioning agents, hair color protectors, scalp care solutions, and anti-microbials. These offerings are integral to products across diverse segments like skin care, hair care, sun protection, oral hygiene, baby care, and household cleaning.
Technical Analysis
Honasa Consumer Limited
―
Jyothy Labs Limited
―
Manorama Industries Ltd.
―
Procter & Gamble Health Ltd.
―
Zydus Wellness Limited
―